June 27th 2025
Roflumilast cream 0.05% is being studied for mild-to-moderate AD in infants aged 3 months to under 2 years in a new phase 2 trial.
Addressing Healthcare Inequities: Tailoring Cancer Screening Plans to Address Inequities in Care
View More
SimulatED™: Understanding the Role of Genetic Testing in Patient Selection for Anti-Amyloid Therapy
View More
Cases and Conversations™: Applying Best Practices to Prevent Shingles in Your Practice
View More
Friction-induced blistering on a child’s feet
July 14th 2023You are called to the hospital nursery to evaluate a healthy full-term newborn boy who developed painful flaccid blisters and erosions on the tops of his feet and ankles shortly after birth. His mother had a history of similar recurrent skin lesions that healed with scarring. She also had oral and gastrointestinal tract involvement. What's the diagnosis?
Higher risk of autoimmune, other disorders associated with children of mothers with alopecia areata
May 26th 2023New data indicates that increased risk for offspring in developing different disorders is associated with maternal alopecia areata exposure, expanding the available information on alopecia and maternal autoimmunity.
FDA approves B-VEC to treat dystrophic epidermolysis bullosa patients 6 months and older
May 19th 2023The FDA has approved Krystal Biotech's beremagene geperpavec (B-VEC) (Vyjuvek; Krystal Biotech) to treat the wounds of dystrophic epidermolysis bullosa (DEB) patients aged 6 months and older. B-VEC is the first FDA-approved gene therapy treatment for DEB, according to the agency. In this Contemporary Pediatrics interview, Raj Chovatiya, MD, PhD, breaks down this much-anticipated FDA approval.
Tapinarof cream 1% demonstrates positive topline results for treating pediatric AD
May 16th 2023The once-daily topical cream for the treatment of atopic dermatitis (AD) has demonstrated positive topline results in 2 phase 3 studies in adults and children aged 2 years and up. According to Dermavant, a supplemental new drug application (sNDA) filed with the FDA is anticipated in Q1 of 2024.
FDA accepts NDA for roflumilast foam 0.3% for seborrheic dermatitis in 9 years and up
April 18th 2023Roflumilast is a once-daily, topical phosphodiesterase type 4 (PDE4) inhibitor under development for treatment of inflammatory dermatoses, focusing on the hair-bearing areas including the face, scalp, and trunk.
Establishing accurate case definitions for childhood respiratory and skin conditions
February 17th 2023A research letter addresses the challenges of accurately diagnosing asthma, atopic eczema, and allergic rhinitis in children under 5 years old and the use of Read codes and prescription data as diagnostic criteria.